1st Quarter 2007

Covance Out In Front

Publications

Bernardo M, Crawford P, Hertel J, Sholer C, Xu X, Goss T, Kewalramani R, Globe D. Assessment of time and practice resources required to provide weekly or monthly erythropoiesis stimulating protein therapy to chronic kidney disease patients in the physician office setting.
Journal of Managed Care Pharmacy 2006; 12(9):714-725.

Goss T, Szende A, Schaefer C, Totten J, Knight R, Jädersten M, Hellström-Lindberg E, List A. Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States.
Cancer Control: Journal of the Moffitt Cancer Center 2006; 13:17-32.

Szende A, Oppe M, Devlin N. EQ-5D value sets: Inventory, comparative review and user guide.
EuroQol Group Monographs 2007; 2.

Abstracts & Presentations

Chidolue F, Glidden D, Blanco B, Xu X, Scharf J, Kewalramani R, Globe D. Comparison of humanistic and economic burden of weekly (QW) versus monthly (QM) erythropoiesis stimulating protein (ESP) therapy for anemia in patients with CKD and their families. Presented at the American Society of Nephrology Renal Week 2006 meeting, San Diego, CA, November 14-19, 2006.
Journal of the American Society of Nephrology 2006;17:622A.

Cramer J, Brandenburg N, Vera-Llonch M, Oster G, Xu X. The impact of seizure and adverse effects on global health ratings. First Annual North American Regional Epilepsy Congress, San Diego, CA, December 1-5, 2006.

Rubin R, Glaspy J, Adams J, Mafilios M, Scharf J, Viswanathan H, Kallich J. Cost-minimization analysis of darbepoetin alfa every three weeks versus weekly epoetin alfa initiated at labeled starting doses for the treatment of chemotherapy-induced anemia. American Society of Health System Pharmacists Midyear Clinical Meeting, Anaheim, CA, December 4, 2006.

Thomas J, Ackerman M, Borden A, Xu X, Goss T, Kewalramani R, Globe D. Comparison of practice resource use and patient burden for weekly (QW) compared to monthly (QM) erythropoiesis stimulating protein (ESP) therapy. Presented at the American Society of Nephrology Renal Week 2006 meeting, San Diego, CA, November 14-19, 2006.
Journal of the American Society of Nephrology 2006;17.

Thomas J, Ackerman M, Borden A, Xu X, Goss T, Kewalramani R, Globe D. Resource use associated with routine erythropoiesis stimulating protein (ESP) therapy in outpatient setting: Assessments from the perspective of practices and patients. Kidney Disease Economic Conference (KDEC), Baltimore, MD, October 27-29, 2006.

Xu X, Zlateva G, Goss T, Buggage R, Cruess A. Impact of bilateral neovascular age-related macular degeneration and related visual impairment on patients' quality of life and functioning: A survey of five countries. Presented at ISPOR 9th Annual European Congress, Copenhagen, Denmark, October 28-31, 2006.
Value in Health 2006;9:A371-A372.

Zlateva G, Xu X, Lenz C, Pauleikhoff D. Humanistic burden and health resource utilization among neovascular age-related macular degeneration (AMD) patients: Results for Germany from a multi-country cross-sectional study. Presented at ISPOR 9th Annual European Congress, Copenhagen, Denmark, October 28-31, 2006.
Value in Health 2006;9:A206-A207.

Conference Presentations

Caroline Schaefer presented “Using a global value dossier to support a successful global launch” at CBI's Pharmaceutical Product Launches, West Conshohocken, PA, December 5-6, 2006.

David Parker, PhD presented “Revolutionary Changes in Medicare's Inpatient PPS - Understanding the Impact and Planning for Product Success” at CBI's Strategic Medicare Compliance Congress, Washington, DC, February 12-13, 2007.

Caroline Schaefer and Edgar Adams, ScD, presented “Leverage Observational Studies to Prove the Scientific Value of Your Trials and to Show Patient Compliance in the ‘Real World'” at CBI's Post-Marketing Studies, London, UK, February 12-13, 2007.

Greg Hall, PD, JD, LLM, presented “Models for Co-Payment Assistance for Commercially Insured and Medicare Patients” at CBI's Patient Assistance Programs, Baltimore, MD, March 5-6, 2007.

Stacey Ackerman, PhD, will present a short course on “Outcomes Research for Medical Devices & Diagnostics” at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 12 th Annual International Meeting, Arlington, VA, May 19-23, 2007.

Kathy Hughes will present “The Importance of ‘Good Science' to Reimbursement: The Use and Credibility of Observational Data in a Post-Market Environment” at SMI's Pharmaceutical Pricing and Reimbursement in North America, London, UK, June 4-5, 2007.

Thomas Goss, PharmD, will present “Increasing Effectiveness of Post-Approval Studies with Pharmacoeconomic and Outcomes Research” at IIR's Post-Approval Research, Philadelphia, PA, June 12-14, 2007.

Awards

Frost & Sullivan awarded Covance for Market Leadership of the Year (excellence in all areas of the market leadership process, including the identification of market challenges, drivers and restraints, as well as strategy development and methods of addressing these market dynamics) and Customer Value Enhancement (ability to expand the customer base, while maintaining its existing install base, with more innovative value creation and enhancement strategies than competing vendors) in the North American Contract Research Organization (CRO) market for 2006.

Appointments